RecruitingNot ApplicableNCT07244939
Cephea South America Feasibility Study
Sponsor
Abbott Medical Devices
Enrollment
20 participants
Start Date
Jun 17, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
The objective of this study is to evaluate the preliminary safety and effectiveness of the Cephea Mitral Valve System for the treatment of symptomatic patients with mitral valve disease (including mitral regurgitation, mitral stenosis and mixed mitral valve disease) in whom transcatheter therapy is deemed more appropriate than open heart surgery.
Eligibility
Min Age: 18 Years
Inclusion Criteria3
- Mitral valve disease resulting in mitral regurgitation (MR ≥ Grade III) and/or severe mitral valve stenosis (mitral valve area ≤ 1.5cm²) per American Society of Echocardiography criteria
- LVEF ≥ 30%
- In the judgement of the Site Heart Team, transcatheter therapy is deemed more appropriate than open heart surgery
Exclusion Criteria2
- Prior surgical or interventional treatment that interferes with the Cephea valve delivery or function
- Need for emergent or urgent surgery
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DEVICECephea Mitral Valve System
Cephea Mitral Valve System
Locations(3)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07244939
Related Trials
A Clinical Study of GeminiOne TEER System for the Treatment of Severe, Symptomatic MR.
NCT070865341 location
Cephea Early Feasibility Study
NCT0506100422 locations
Abbott Cephea Mitral Valve Disease Registry
NCT0706967319 locations
STrategies for Antithrombotic tReatment Following Transcatheter Edge-to-Edge Repair in Patients With an Indication for Oral Anticoagulant
NCT069014661 location
STrategies for Antithrombotic tReatment Following Transcatheter Edge-to-Edge Repair in Patients Without an Indication for Oral Anticoagulant
NCT070071431 location